HomeCompareGDNPF vs PFE

GDNPF vs PFE: Dividend Comparison 2026

GDNPF yields 50000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GDNPF wins by $4.789070889867552e+23M in total portfolio value
10 years
GDNPF
GDNPF
● Live price
50000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.789070889867552e+23M
Annual income
$477,030,307,353,597,400,000,000,000,000.00
Full GDNPF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GDNPF vs PFE

📍 GDNPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGDNPFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GDNPF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GDNPF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GDNPF
Annual income on $10K today (after 15% tax)
$4,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$405,475,761,250,557,800,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GDNPF beats the other by $405,475,761,250,557,800,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GDNPF + PFE for your $10,000?

GDNPF: 50%PFE: 50%
100% PFE50/50100% GDNPF
Portfolio after 10yr
$2.394535444933776e+23M
Annual income
$238,515,153,676,798,700,000,000,000,000.00/yr
Blended yield
99.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GDNPF
No analyst data
Altman Z
-1.6
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GDNPF buys
0
PFE buys
0
No recent congressional trades found for GDNPF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGDNPFPFE
Forward yield50000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.789070889867552e+23M$49.6K
Annual income after 10y$477,030,307,353,597,400,000,000,000,000.00$26,258.71
Total dividends collected$4.7878388715795706e+23M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GDNPF vs PFE ($10,000, DRIP)

YearGDNPF PortfolioGDNPF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$5,010,700$5,000,000.00$9,153$693.39+$5.00MGDNPF
2$2,346,810,047$2,341,448,598.13$8,593$849.25+$2346.80MGDNPF
3$1,027,408,478,283$1,024,897,391,532.38$8,336$1,066.78+$1027408.47MGDNPF
4$420,435,006,832,721$419,335,679,760,958.80$8,437$1,384.80+$420435006.82MGDNPF
5$160,823,792,302,236,830$160,373,926,844,925,820.00$9,013$1,875.40+$160823792302.23MGDNPF
6$57,504,652,079,586,796,000$57,332,570,621,823,390,000.00$10,306$2,680.72+$57504652079586.79MGDNPF
7$19,220,418,850,978,506,000,000$19,158,888,873,253,350,000,000.00$12,820$4,101.38+$19220418850978508.00MGDNPF
8$6,005,321,287,350,842,000,000,000$5,984,755,439,180,295,000,000,000.00$17,673$6,826.70+$6005321287350842368.00MGDNPF
9$1,754,001,526,315,678,800,000,000,000$1,747,575,832,538,213,200,000,000,000.00$27,543$12,591.86+$1.7540015263156787e+21MGDNPF
10$478,907,088,986,755,200,000,000,000,000$477,030,307,353,597,400,000,000,000,000.00$49,560$26,258.71+$4.789070889867552e+23MGDNPF

GDNPF vs PFE: Complete Analysis 2026

GDNPFStock

good natured Products Inc., together with its subsidiaries, designs, produces, and distributes bioplastics for use in packaging and durable product applications in Canada and the United States. It offers packaging products for baked goods, deli and prepared meals, and fruits and veggies; home and business products, including bins, totes and crates, and food storage and bin liners; pallet stretch wraps, rollstocks, and resins; compostable take out containers, such as hot cups and lids, plates, carry out boxes, cutlery, and soup bowls and lids; and plastic sheet and film products, including extruded roll stock sheets for thermoformed packaging. The company was formerly known as Solegear Bioplastic Technologies Inc. and changed its name to good natured Products Inc. in October 2017. good natured Products Inc. was founded in 2006 and is headquartered in Vancouver, Canada.

Full GDNPF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GDNPF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GDNPF vs SCHDGDNPF vs JEPIGDNPF vs OGDNPF vs KOGDNPF vs MAINGDNPF vs JNJGDNPF vs MRKGDNPF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.